KALY - Kali-Extracts Sales Grow With Potential For $1 Million In Total 2019 Revenue
27 November 2019 - 1:25AM
InvestorsHub NewsWire
KALY - Kali-Extracts Sales Grow
With Potential For $1 Million In Total 2019 Revenue
Dallas, TX --
November 26, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today published a financial performance update
in conjunction with KALY’s financial performance report through
September 30, 2019.
KALY’s current
revenues come primarily from the sale of CBD infused products that
have utilized KALY’s U.S. Patented Cannabis Extraction
Process. KALY produces its own line of CBD infused candies
under the Hemp4mula brand name. Hemp4mula includes both CBD
Gum and CBD Gummies. Both are available at www.USMJ.com. KALY has also licensed its
Patented Cannabis Extraction Process for the production of CBD and
cannabis infused beverages.
KALY has
reported $173,300 for the three-month period ending September 30,
2019. KALY’s year to date revenue through the period ending
September 30, 2019 exceeds $300,000. The company’s operation
is profitable.
After executing
its first CBD extraction contracts with hemp farming operations and
commencing its first harvesting and extraction efforts, management
anticipates a substantial addition to sales in the fourth quarter
adding to ongoing sales generated from CBD infusion into candies
and beverages that could bring the company close to or over $1
million in sales for 2019.
KALY’s infusion
and extraction business supplements the company’s primary cannabis
biopharmaceutical technology development objectives. To date, KALY
has an intellectual property portfolio that contains a deep
pipeline of cannabinoid biopharmaceutical product candidates
including four distinct compounds listed
here:
Chronic Obstructive Pulmonary
Disease (COPD) - The
market for COPD treatment is anticipated to reach $14 billion by
2025;
Type 2
Diabetes - The market for
Type 2 Diabetes is expected to be a $64 billion market by
2026;
Cancer Pain
Management - The overall
pain management treatment market is anticipated to reach $83
billion by 2024, and
Epilepsy
- The market for epilepsy treatment is
anticipated to reach $9 billion by 2022.
In conjunction with the research already conducted
and the next phase of research now moving forward, KALY recently
filed for a new patent application specifically on its formulation
for symptoms associated with COPD and other similar respiratory
conditions. KALY also filed for a trademark
on the name RespRx as the brand name for its CBD
formulation to treat the symptoms associated with COPD and other
similar respiratory conditions. The market
for COPD treatment is anticipated to reach $14 billion by
2025.
In addition to KALY’s ongoing efforts to develop
prescription therapies, KALY has initiated a program to certify its
proprietary CBD extracts derived from KALY’s U.S. Patented
Extraction Process as an Over-The-Counter (OTC) drug under the
requirements prescribed by the U.S. Food and Drug
Administration.
KALY has
recently announced receiving two inquiries into the acquisition of
the company’s cannabis biopharmaceutical technology valuing the
technology at $50 million. KALY management is entertaining
the inquiries but indicates that the $50 million valuation is too
low. Doctors working with KALY on the treatment developments
have compared KALY’s technology to GW Pharmaceuticals’ and
indicated the KALY solutions could be superior to GW
Pharma’s. KALY management has also recently announced that in
addition to entertaining the two acquisition opportunities that
could infuse financing that accelerates its cannabis extract
biopharmaceutical technology developments, that the company is
introducing a third option that would not involve a sale of KALY’s
biopharmaceutical technology asset, but would otherwise restructure
the asset within KALY’s current corporate structure to facilitate a
major infusion of investment capital. KALY management plans to
finalize the third option plans within the next two weeks and make
them public.
KALY is
currently endeavoring to update its status with OTC Markets. In the
meantime, KALY self-discloses at www.kaly-info.com. The financial report
for the three-month period ending September 30, 2019 can be found
at www.kaly-info.com/Q3-RPT.
To stay abreast
of the latest developments and learn more about the company visit
https://www.kali-extracts.com/.
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Apr 2024 to May 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Kali Inc (CE) (OTCMarkets): 0 recent articles
More Kali, Inc. (PN) News Articles